# IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

> **NCT01480986** · PHASE2 · COMPLETED · sponsor: **Peking University** · enrollment: 40 (actual)

## Conditions studied

- Progression Free Survival of the Treatment

## Interventions

- **DRUG:** Irinotecan combined with cisplatin, octreotide lar

## Key facts

- **NCT ID:** NCT01480986
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480986, "IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01480986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*